These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25829129)

  • 1. Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia.
    Sahebkar A; Badiee A; Hatamipour M; Ghayour-Mobarhan M; Jaafari MR
    Colloids Surf B Biointerfaces; 2015 May; 129():71-8. PubMed ID: 25829129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes.
    Sahebkar A; Badiee A; Ghayour-Mobarhan M; Goldouzian SR; Jaafari MR
    Colloids Surf B Biointerfaces; 2014 Oct; 122():645-652. PubMed ID: 25139293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negatively-charged Liposome Nanoparticles Can Prevent Dyslipidemia and Atherosclerosis Progression in the Rabbit Model.
    Momtazi-Borojeni AA; Abdollahi E; Jaafari MR; Banach M; Watts GF; Sahebkar A
    Curr Vasc Pharmacol; 2022; 20(1):69-76. PubMed ID: 34414873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple and rapid-acting approach for the reduction of C-reactive protein.
    Momtazi-Borojeni AA; Ayati SH; Jaafari MR; Sahebkar A
    Biomed Pharmacother; 2019 Jan; 109():2305-2308. PubMed ID: 30551488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials.
    Panta R; Dahal K; Kunwar S
    J Clin Lipidol; 2015; 9(2):217-25. PubMed ID: 25911078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lipid composition on incorporation of trastuzumab-PEG-lipid into nanoliposomes by post-insertion method: physicochemical and cellular characterization.
    Golkar N; Tamaddon AM; Samani SM
    J Liposome Res; 2016; 26(2):113-25. PubMed ID: 26023889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
    Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
    Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic Nanoliposomes Are Efficiently Taken up by Alveolar Macrophages but Have Little Access to Dendritic Cells and Interstitial Macrophages in the Normal and CpG-Stimulated Lungs.
    Vanbever R; Loira-Pastoriza C; Dauguet N; Hérin C; Ibouraadaten S; Vanvarenberg K; Ucakar B; Tyteca D; Huaux F
    Mol Pharm; 2019 May; 16(5):2048-2059. PubMed ID: 30965005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and characterization of alprazolam-loaded nanoliposomes: screening of process variables and optimizing characteristics using RSM.
    Hashemi SH; Montazer M; Naghdi N; Toliyat T
    Drug Dev Ind Pharm; 2018 Feb; 44(2):296-305. PubMed ID: 29022858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation.
    Van Haute D; Jiang W; Mudalige T
    Int J Pharm; 2019 Oct; 569():118603. PubMed ID: 31401296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do the physicochemical properties of nanoliposomes affect their interactions with the hCMEC/D3 cellular model of the BBB?
    Papadia K; Markoutsa E; Antimisiaris SG
    Int J Pharm; 2016 Jul; 509(1-2):431-438. PubMed ID: 27286634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma.
    Alavizadeh SH; Badiee A; Golmohammadzadeh S; Jaafari MR
    Int J Pharm; 2014 Oct; 473(1-2):326-33. PubMed ID: 25051111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-oxidant and anti-atherogenic properties of liposomal glutathione: studies in vitro, and in the atherosclerotic apolipoprotein E-deficient mice.
    Rosenblat M; Volkova N; Coleman R; Aviram M
    Atherosclerosis; 2007 Dec; 195(2):e61-8. PubMed ID: 17588583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell association of liposomes with high fluid anionic phospholipid content is mediated specifically by LDL and its receptor, LDLr.
    Amin K; Wasan KM; Albrecht RM; Heath TD
    J Pharm Sci; 2002 May; 91(5):1233-44. PubMed ID: 11977099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
    Tardy C; Goffinet M; Boubekeur N; Ackermann R; Sy G; Bluteau A; Cholez G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R
    Atherosclerosis; 2014 Jan; 232(1):110-8. PubMed ID: 24401224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.